Cytek Biosciences (NASDAQ:CTKB) Earns “Overweight” Rating from Stephens
Cytek Biosciences (NASDAQ:CTKB – Get Free Report)‘s stock had its “overweight” rating restated by Stephens in a research report issued to clients and investors on Wednesday,Benzinga reports. They currently have a $6.00 price objective on the stock. Stephens’ target price points to a potential upside of 47.78% from the company’s current price. CTKB has been […]
Cytek Biosciences (NASDAQ:CTKB – Get Free Report)‘s stock had its “overweight” rating restated by Stephens in a research report issued to clients and investors on Wednesday,Benzinga reports. They currently have a $6.00 price objective on the stock. Stephens’ target price points to a potential upside of 47.78% from the company’s current price. CTKB has been […]
